Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells
Molecular Oncology, EarlyView.We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller +17 more
wiley +1 more source
Application of the indirect fluorescent antibody assay in the study of malaria infection in the Yangtze River Three Gorges Reservoir, China [PDF]
, 2009 Duoquan Wang +4 more
openalex +1 more source
Epitope analysis of human monoclonal antibodies from a patient with autoimmune factor
, 2023 Tsukasa Osaki +4 more
openalex +1 more source
Molecular Oncology, EarlyView.The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola +12 more
wiley +1 more source
The Evolution and Development of the Antibody Repertoire [PDF]
, 2015 Harry W. Schroeder
openalex +1 more source
Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity [PDF]
, 2023 Yulia Desheva +7 more
openalex +1 more source
ATF4‐mediated stress response as a therapeutic vulnerability in chordoma
Molecular Oncology, EarlyView.We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone +11 more
wiley +1 more source
Anti-PLA2R antibody reduction as a predictor of treatment response in primary membranous nephropathy: a retrospective study. [PDF]
J Bras NefrolBashir K +6 more
europepmc +1 more source
A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy
Molecular Oncology, EarlyView.Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti +3 more
wiley +1 more source
Biologics: Targets & TherapyRun Cao,* Wenqing Qi,* Xinyu Huang, Yalun Zheng, Rudan Zheng, Yuanfang Ma, Hailong Zhang Joint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital, Henan University, Kaifeng, Henan, People’s Republic of China ...
Cao R +6 more
doaj